Levamisole is an anthelmintic agent that exerts its therapeutic effect by acting as a full agonist of the nicotinic receptor (AChR) of nematode muscle. Its action at the mammalian muscle AChR has not been elucidated to date despite its wide use as an anthelmintic in humans and cattle. By single channel and macroscopic current recordings, we investigated the interaction of levamisole with the mammalian muscle AChR. Levamisole activates mammalian AChRs. However, single channel openings are briefer than those activated by acetylcholine (ACh) and do not appear in clusters at high concentrations. The peak current induced by levamisole is about 3% that activated by ACh. Thus, the anthelmintic acts as a weak agonist of the mammalian AChR. Levamisole also produces open channel blockade of the AChR. The apparent affinity for block (190 M at ؊70 mV) is similar to that of the nematode AChR, suggesting that differences in channel activation kinetics govern the different sensitivity of nematode and mammalian muscle to anthelmintics. To identify the structural basis of this different sensitivity, we performed mutagenesis targeting residues in the ␣ subunit that differ between vertebrates and nematodes. The replacement of the conserved ␣Gly-153 with the homologous glutamic acid of nematode AChR significantly increases the efficacy of levamisole to activate channels. Channel activity takes place in clusters having two different kinetic modes. The kinetics of the high open probability mode are almost identical when the agonist is ACh or levamisole. It is concluded that ␣Gly-153 is involved in the low efficacy of levamisole to activate mammalian muscle AChRs.
At the neuromuscular junction, acetylcholine (ACh) 1 mediates fast neurotransmission by activating nicotinic receptors (AChRs). AChRs in nematode muscle are targets for anthelmintic chemotherapy. Levamisole and pyrantel are two widely used anthelmintic drugs. By binding to the AChR they lead to a depolarization of the somatic muscle of nematodes. The efficacy of these drugs is based on their ability to act as full agonists of AChRs in nematodes (1) . Contractility and membrane potential measurements have shown that the nematode axial muscle is 10 -100 times more sensitive to the acute action of pyrantel and levamisole than the rat muscle (2) . The molecular bases of this selectivity have not been yet elucidated. The kinetics of activation of nematode AChRs by levamisole has been studied in several preparations from parasite muscle (1, 3) , but its action on mammalian muscle AChRs has not been described to date. The effects of levamisole on human neuronal ␣ 3 ␤ 2 and ␣ 3 ␤ 4 AChRs have been studied recently (4) with the voltage clamp method. It was shown that levamisole behaves as a weak partial agonist, an allosteric modulator, and an open channel blocker of neuronal AChRs (4) .
ACh is responsible for neuromuscular transmission in nematodes (1) . In Caenorhabditis elegans muscle, levamisoleactivated AChRs are composed of the unc-38 subunit, which encodes an ␣ subunit, and lev-1 and unc-29, which encode non-␣ subunits (5) . Expression studies in Xenopus oocytes have shown that both unc-38 and unc-29 subunits are necessary for AChR function (5) . Both subunits are required for the expression of levamisole-sensitive receptors in body wall muscles of these nematodes (6) . Other nematode ␣ subunits have been cloned from the parasitic nematodes Trichostrongylus colubriformis (7) , Haemonchus conturtus (8) , and Ascaris suum (9) , showing a 91.6, 91, and 76% similarity with unc-38, respectively. The main structural features of the AChR subunits are strikingly conserved in phylogeny from higher organisms to the nematode. However, residues differentially conserved between mammalian and nematode AChRs may lead to a differential pharmacological action of anthelmintics at AChRs.
In this study, we explore for the first time the interaction of levamisole with mammalian muscle AChRs at the single channel and macroscopic current levels. Our results reveal that levamisole shows an extremely low efficacy for channel activation. At high levamisole concentrations, channel blockade also contributes to maintain a low probability of channel opening. In contrast, levamisole has been shown to act as a potent agonist of different nematode muscle AChRs (3, 10 -12) . Thus, this anthelmintic compound therapeutically exploits differences by selectively activating the AChR of the parasite and not that of the host. To identify residues involved in this different selectivity, we combined site-directed mutagenesis at residues differentially conserved between muscle ␣ subunits from nematodes and vertebrates, and we evaluated the changes in levamisole activation. Our results reveal that the glutamic acid at position 153, which is highly conserved in all nematode ␣ subunits cloned to date, may be involved in the potent activation of nematode AChRs by levamisole.
The elucidation of the molecular basis of anthelmintic acti-vation of AChRs will greatly contribute to the development of more selective therapies against parasites and to the understanding of how parasites develop resistance to the anthelmintics. In addition, it pinpoints determinants of function.
EXPERIMENTAL PROCEDURES
Site-directed Mutagenesis and Expression of AChR-HEK293 cells were transfected with mouse ␣ (wild-type or mutant), ␤, ␦, and ⑀ cDNAs using calcium phosphate precipitation at a subunit ratio of 2:1:1:1 for ␣:␤:␦:⑀, respectively, mainly as described previously (13, 14) . A plasmid encoding green fluorescent protein (pGreen lantern) was also included for recordings to allow identification of transfected cells under fluorescence optics. Mutant subunits were constructed using the QuikChange TM site-directed mutagenesis kit (Stratagene). Restriction mapping and DNA sequencing confirmed all constructs. Cells were used for patch clamp recordings 48 h after transfection.
Patch Clamp Recordings and Kinetic Analysis-Recordings were obtained in the cell-attached configuration (15) at 20°C (13) . The bath and pipette solutions contained 142 mM KCl, 5.4 mM NaCl, 1.8 mM CaCl 2 , 1.7 mM MgCl 2 , and 10 mM HEPES (pH 7.4). Acetylcholine (ACh), levamisole (Sigma), or both drugs were added to the pipette solution. Single channel currents were recorded using an Axopatch 200 B patch clamp amplifier (Axon Instruments, Inc., CA), digitized at 5-s intervals with the PCI-611E interface (National Instruments, Austin, TX), recorded to the hard disk of a computer using the program Acquire (Bruxton Corporation, Seattle, WA), and detected by the half-amplitude threshold criterion using the program TAC 4.0.10 (Bruxton Corporation, Seattle, WA) at a final bandwidth of 10 kHz. Open and closed time histograms were plotted using a logarithmic abscissa and a square root ordinate and fitted to the sum of exponentials by maximum likelihood using the program TACFit (Bruxton Corp., Seattle, WA).
Clusters were identified as a series of closely spaced events preceded and followed by closed intervals longer than a specified duration (t crit ); this duration was taken as the point of intersection of the predominant closed time component and the succeeding one in the For the analysis, we only used clusters that showed only one gating mode. For the high P open mode activated by ACh and levamisole, the kinetic analysis was restricted to clusters, each reflecting the activity of a single AChR (16 -18) . The resulting open and closed intervals from the selected clusters were analyzed according to kinetic schemes using an interval-based full-likelihood algorithm (www.qub.buffalo. edu) (QuB suite, State University of New York, Buffalo). The dead time was typically 30 s. Probability density functions of open and closed durations were calculated from the fitted rate constants and instrumentation dead time and superimposed on the experimental dwell time histogram as described by Qin et al. (19) . Calculated rates were accepted only if the resulting probability density functions correctly fitted the experimental open and closed duration histograms.
The other approach was applied to the low P open gating mode of the ␣G153E AChR and to wild-type AChRs activated by levamisole, in which less clear or no clusters were observed. We analyzed the behavior of bursts of single channel activity elicited by low agonist concentrations, where no clusters can be seen and block is insignificant, on the basis of the classical activation Scheme 1,
where two agonists (A) bind to the receptor (R) in the resting state with association rates k ϩ1 and k ϩ2 and dissociate with rates k Ϫ1 and k Ϫ2 . AChRs occupied by two agonist molecules open with rate ␤ and close with rate ␣. Bursts at low agonist concentrations contain information about the open state and the immediately adjacent closed state (16) . Therefore, estimates of ␤, ␣, and k Ϫ2 can be obtained from the mean duration of the briefer component of the closed time histogram ( c ), its relative area (A c ), and the mean burst duration ( b ) as follows:
Macroscopic Current Recordings-For outside-out patch recordings, the pipette solution contained 140 mM KCl, 5 mM EGTA, 5 mM MgCl 2 , and 10 mM HEPES (pH 7.3). Extracellular solution contained 150 mM NaCl, 5.6 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM HEPES (pH 7.3). The patch was excised in this configuration and moved into position at the outflow of a perfusion system as described before (20, 21) . The perfusion system allows for a rapid (0.1-1 ms) exchange of the solution bathing the patch. A series of applications of extracellular solution containing ACh, levamisole, or both drugs were applied to the patch during 150 ms. Macroscopic currents were filtered at 5 kHz, digitized at 20 kHz, and stored on the hard disk. Data analysis was performed using the IgorPro software (WaveMetrics Inc., Lake Oswego, OR). The ensemble mean current was calculated for 5-10 individual current traces. Mean currents were usually fitted by a single exponential function: I (t) ϭ I 0 exp(Ϫt/ d ) ϩ I ϱ where I 0 and I ϱ are the peak and the steady state current values, respectively, and d is the decay time constant that measures the current decay due to desensitization. Current records were aligned with each other at the point where the current reached 50% of its maximum level.
RESULTS

Activation of Mammalian AChRs by Levamisole
Single Channel Currents Activated by Levamisole-Levamisole is a full agonist of the nematode muscle AChR (1). In the present study, we evaluated if this anthelmintic drug also acts on mammalian muscle AChRs. To this end, we first recorded single channels from cells expressing adult muscle AChRs ( Macroscopic Currents Activated by Levamisole-To evaluate the efficacy of levamisole in activating mammalian AChRs, we recorded macroscopic currents from outside-out patches rapidly perfused with levamisole. Fig. 2 shows ensemble currents obtained from a single outside-out patch exposed to brief applications of 100 M ACh (control) and 100 M levamisole. In control data, the current reaches the peak after 0.1-1 ms and then decays with a time constant ( d ) of about 20 -30 ms due to desensitization ( Fig. 2) (20) . The peak current is only about 3% when the same patch is exposed to 100 M levamisole. Moreover, in many patches only single channels were observed after perfusion with levamisole. These results confirm the low efficacy of the drug to activate mammalian AChRs.
Open Channel Blockade of AChRs by Levamisole
Given that the single channel recording experiments suggest that levamisole may also block AChRs (Fig. 1) , we studied its action as a channel blocker in the absence and presence of ACh. Increasing levamisole concentration systematically displaces (Fig. 4a ). The calculated value for the forward rate constant of the blocking reaction (k ϩb in Scheme 2), given by the slope of the curve, is 30 ϫ 10 6 and 25 ϫ 10 6 M Ϫ1 s Ϫ1 for ACh-or levamisole-activated channels. Thus, AChRs activated by either ACh or levamisole are blocked by levamisole at a similar rate. The apparent closing rate, calculated from the intercept with the y axis, is 5600 s Ϫ1 for levamisole-activated AChRs and 1600 s Ϫ1 for ACh-activated channels. This value agrees with the closing rate of ACh-activated channels calculated by kinetic analysis (17, 18) .
To analyze the blockade by levamisole, we studied the closed time distributions of AChRs activated by 1 M ACh in the presence of levamisole. In its absence, closed time histograms corresponding to 1 M ACh-activated channels show a main component whose duration is dependent on the number of channels in the patch (17) (Fig. 3) . The presence of levamisole significantly changes the closed time distributions of AChactivated channels, and a new closed component of about 175 s is systematically observed (Fig. 3 ). The duration of this component does not change with levamisole concentration, but its area increases as a function of its concentration (Fig. 4b) . It is therefore possible to assume that this closed component corresponds to the blockade by levamisole of the ACh-activated channels (1/k Ϫb in Scheme 2). From the duration of this closed component (1/k Ϫb ) a value of 5700 s Ϫ1 is obtained for k Ϫb . Thus, the apparent dissociation constant for the blocking process,
At levamisole concentrations higher than 100 M, the blocked area does not increase as a function of concentration. The values for the closed components and relative areas are 175 Ϯ 12 s and 0.32 Ϯ 0.03, and 220 Ϯ 15, and 0.33 Ϯ 0.08 s for 100 and 300 M levamisole, respectively. Therefore, at higher concentrations the channel block mechanism deviates from Scheme 2.
The duration of the blocked periods increases with higher negative membrane potentials, indicating that the unblocking process is voltage-dependent (Fig. 4c ). The voltage dependence of the effect is confirmed by outside-out patch recordings ( Fig.  4d ). At positive membrane potentials, 100 M levamisole does not affect the decay constant of currents elicited by 1 mM ACh, and the data can be fitted by a single exponential decay similar to the control (22.5 ms). In contrast, at Ϫ70 mV, an initial fast decay precedes desensitization. This fast component (about 0.5 ms) is due to open channel blockade. The slow decay time constant, which corresponds to desensitization, is 19.4 Ϯ 1.8 ms. The peak current is not affected, suggesting that at the ratio of concentrations that are used, levamisole cannot compete with ACh for channel activation. In short, the characterization of the blockade indicates that levamisole acts as a typical open channel blocker at concentrations below 100 M.
Structural Basis of the Weak Activation of Mammalian AChRs by Levamisole
Sequence comparison reveals key residues that are differentially conserved between mammalian and nematode muscle ␣ subunits (Fig. 5 ). To identify if these residues are involved in the differential behavior of anthelmintic drugs at parasite and mammalian muscle, we replaced them by the equivalent residues in nematodes, cotransfected cells with the mutant ␣ and wild-type non-␣ subunits, and we evaluated channel activity elicited by levamisole. The efficacy of levamisole to activate mammalian AChRs is greatly increased when the residue ␣Gly-153 is replaced by a glutamic acid. As shown in Fig. 6 , channel activity appears now in easily recognizable clusters at 50 M levamisole. In contrast, no changes are observed in the activation by levamisole (1-100 M) of AChRs carrying either the mutations ␣D152S, ␣S154N, or the insertion of a proline after ␣Tyr-190 (␣191insP).
Clusters of ␣G153E AChR can be identified at concentrations higher than 10 M. The clustering of opening events is accompanied by important changes in the closed time histograms. The main component of the closed time distributions, which corresponds to closings within clusters, is displaced to briefer durations as a function of levamisole concentration (Fig. 7) .
To uncover the mechanistic consequences of the presence of a glutamic acid at ␣153, we recorded channels activated by a range of levamisole concentrations (0.1 nM to 300 M) and analyzed the activity of single channel openings in clusters. In parallel, we compared the kinetics of activation by the full agonist ACh.
When examined in detail, it can be observed that clusters of ␣G153E activated by either ACh or levamisole are not homogeneous, indicating that this mutant receptor activates in distinct kinetic modes (Fig. 8) . The distribution of P open values showed two different components (see "Experimental Procedures"). We therefore classified the clusters as belonging to two main gating modes: an HP open and an LP open mode. At all agonist concentrations, the HP open mode consisted of openings that were significantly longer and closings within clusters that were briefer than those of the LP open mode (Table I) the P open distributions, we selected the clusters corresponding to each mode and analyzed them as a function of agonist concentration (Table I and Fig. 8) .
High P open Clusters-At very low concentrations of ACh or levamisole (0.1 nM to1 M), only clusters corresponding to the high P open gating mode can be observed (Fig. 8 ). The rest of the openings appear as isolated events. The P open calculated for these clusters is about 1 at 1 nM of either agonist. Most interestingly, there are no significant differences in the properties between ACh-or levamisole-activated clusters ( Fig. 8 and Table I). Therefore, at low agonist concentrations, levamisole activation of the ␣G153E AChR seems to be kinetically indistinguishable from ACh activation. Clusters of the HP open mode are also observed at higher concentrations of both agonists. However, the mean channel duration as well as the P open decrease at higher concentrations of levamisole due to channel blockade (Table I) .
Low P open Clusters-As the agonist concentration is increased, clusters of the LP open gating mode can be distinguished (Fig. 8) . In contrast to what we observed for the high P open clusters, the low P open ones show marked differences between ACh and levamisole (Table I and Fig. 8 ). In the presence of ACh, low P open clusters are clearly identified at concentrations higher than 10 M. The P open of these clusters increases as a function of ACh and reaches a value of about 0.9 at 100 M ACh (Table I ). In addition, the mean open channel duration remains constant, and the mean closed duration within clusters decreases as ACh concentration is increased, indicating that they correspond to agonist-sensitive activation episodes. When levamisole is used as an agonist, low P open clusters can be identified also at concentrations higher than 10 M. The closed durations separating openings within these clusters decrease as a function of levamisole, as observed for ACh (Table I) (Table I) .
To determine the total contribution of the HP open mode to levamisole activation, we thoroughly examined clusters and quantified the proportion of activation episodes corresponding to this mode. Mode switches occur either between clusters or during the course of a single cluster. 
Kinetics of Activation of Wild-type and ␣G153E AChRs by Levamisole
Results from the burst analysis of wild-type AChRs activated by levamisole show a profound decrease in the opening rate (␤ in Scheme 1) and a 470-fold decrease in the gating equilibrium constant (), calculated as ␤/␣, compared with wild-type AChRs activated by ACh (Table II) . Thus, the resulting analysis establishes that levamisole is a weak agonist of the AChR mainly due to a very low efficacy for activation. The estimated rates also show that the gating equilibrium constant for the low P open mode of ␣G153E activated by levamisole is 7-fold higher than that of wild-type AChRs (Table II) .
For the HP open gating mode, we selected clusters for both (Table I) . We therefore used the data obtained at concentrations of ACh and levamisole lower than 1 M and 10 nM, respectively. Based on this scheme, the kinetic analysis yielded estimates for the rate constants describing the activation process for both ACh and levamisole. Probability density functions computed from the fitted rate constants superimposed upon open and closed time histograms, showing that activation is adequately described by the scheme. The estimated rate constants are similar for ACh-and levamisole-activated AChRs (Table II) . It can therefore be concluded that ␣G153E shows a gating mode which is highly sensitive to the agonist and is similarly activated by levamisole and ACh.
Position 153 has been detected previously in a slow channel congenital myasthenic patient (␣G153S; see Ref. 22 ). We studied the activation of this mutant AChR by 50 M levamisole and compared it with that of ␣G153E. At 50 M levamisole, single channel recordings show clusters of openings, indicating that levamisole is more efficient to activate ␣G153S than wild-type AChRs. However, there are some interesting differences with respect to levamisole activation of ␣G153E. (Table I) . 2) Well defined clusters of the ␣G153S occur at levamisole concentrations higher than 30 M, but the threshold for forming clusters is 10 M for ␣G153E AChRs. Therefore, it seems likely that both the position and the type of amino acid are important in making AChRs highly sensitive to anthelmintics.
DISCUSSION
Levamisole contracts the cut-worm preparation in C. elegans, depolarizes and produces spastic paralysis of A. suum muscle cells, and activates strongly all nematode muscle AChRs (3, 10, 23). Measurements of muscle contractility and membrane potential have shown that the spastic contraction evoked by levamisole is quantitatively similar to that evoked by ACh in the muscle of H. contortus, which is 10 -100 times more sensitive to the acute action of levamisole than the rat muscle (2) .
We elucidated why mammalian muscles show lower sensitivity to the widely used anthelmintic agent levamisole than parasitic muscle, and we identified residues involved in such differential sensitivity. Our studies at the molecular level show for the first time that levamisole is a very weak agonist of mammalian muscle AChRs and reveal the basis of the low opening probability of mammalian AChR by anthelmintics, i.e. an extremely low efficacy for channel activation. In addition, the low efficacy of levamisole is impaired as a function of its concentration due to channel blockade. By site-directed mutagenesis we show that ␣Glu-153, which is conserved in all ␣ subunits of muscle nematode, could be involved in the high efficacy of levamisole at nematode AChRs.
The weak activation process of wild-type mammalian AChRs by levamisole is revealed as follows: (i) the absence of clustering over a range of levamisole concentrations, i.e. AChR channels activated by levamisole, do not cluster at any concentration, whereas clear clusters of activation periods occur at ACh concentrations higher than 10 M. In contrast, it has been shown that both ACh and levamisole activate channels in the same concentration range (1-100 M) in nematode muscle (3) .
(ii) The reduced current elicited by rapid perfusion with levamisole compared with that activated by ACh. A similar result has been described for the partial agonist decamethonium, which produces a peak current of about 1% that activated by the same concentration of ACh (24) . Thus, in contrast to what is observed in the nematode, kinetics of levamisole-activated mammalian AChRs greatly differ from those of AChRs activated by the natural neurotransmitter ACh. The mutation ␣G153E profoundly increases the efficacy of levamisole as an agonist of mammalian AChRs. Two different gating modes can be clearly distinguished in this mutant AChR on the basis of their probability of channel opening. Heterogeneous kinetics have been reported before in wild-type AChRs (25) , and the number and range of kinetic modes have been shown to increase in mutant AChRs (26, 27) . The analysis reveals that at concentrations low enough to avoid channel blockade, the kinetics of activation of the high P open mode is almost indistinguishable for ACh or levamisole, thus supporting the effectiveness of levamisole in chemotherapy against parasites.
The mutant ␣G153S has been detected in patients affected by a slow-channel congenital myasthenic syndrome (22) . Single channel kinetic analysis of engineered ␣G153S AChRs has revealed a markedly decreased rate of ACh dissociation, which causes the mutant AChR to open repeatedly during ACh occupancy (22) . More recently, it has been reported that the mutation to lysine in the homologous position of the ␣7-5HT 3 subunit (G152K) conferred high affinity binding for agonists together with an increase in potency (28) . Kinetic analysis of this mutant receptor suggested that the mutation affects primarily the conformational transition of activation between the closed and open channel states of the AChR (28) . Our results show that the mutation to glutamic acid increases the efficacy of the agonists, but the increase is selectively higher for levamisole than for ACh. Comparison of levamisole activation be-tween ␣G153S and ␣G153E shows that the type of amino acid at this position is also important to determine the kinetic changes.
The mechanistic bases for the kinetic changes described for the ␣G153E AChR may be interpreted on the basis of Scheme 4,
In Scheme 4, resting (R) and active (R*) states of the receptor spontaneously interconvert in the absence of agonist, and activation is driven by progressive occupancy of the sites together with tighter binding of agonist to the active state compared with the resting state. Consistent with its physiological role, the gating reaction of diliganded AChRs is much more favorable than that of unliganded AChRs (29) . From the thermodynamic principle of detailed balance, it follows that 2 ϭ 0 (K 1 K 2 /K 1 *K 2 *). This equation predicts that an increase in 2 may be because of the enhanced binding of agonist to the open relative to closed state of the mutant AChR or to an effect on gating of the channel in the absence of agonist. Given that the residue 153 has been shown to be involved in agonist binding, it is probable that the mutation may affect the affinity ratio of closed and open state and that these changes are more significant for levamisole than for ACh. The mutated amino acids form part of two different binding loops, B (␣Asp-152, ␣Gly-153, and ␣Ser-154) and C (␣-ins191), which contain residues directly contributing to the ACh binding pocket in ␣ subunits (30, 31) . Although form a barrier to entry and escape of agonist (30, 31) , a proline insertion in position 191 does not introduce changes in the activation by levamisole of the AChR. This observation is consistent with the lack of effects reported previously (32) for mutations of other nearby residues. Mutations at positions 152 and 154 of ␣7 produced an increase in apparent binding affinity for ACh and nicotine (33) . However, the most significant effects were introduced by mutations at position 153 (33) .
In addition to its weaker agonist activity, levamisole acts as a more potent blocker than ACh. Hallmarks of an open channel blockade process are as follows: (i) a concentration-dependent decrease in the mean open time; (ii) a concentration-dependent increase in the fractional area of the block component; and (iii) constant mean duration of the blocked intervals across all blocker concentrations (34) . These statements are confirmed at levamisole concentrations lower than 100 M, indicating that this drug acts as an open channel blocker of mammalian AChRs. At higher concentrations, the observed blocking mechanism deviates from that of classical open channel blockers. Deviations from the linear open channel block mechanism have been also described for many noncompetitive antagonists at high concentrations (35, 36) . Our findings can be explained by the fact that the blocked receptor may close, with or without trapping the blocker molecule in its site (37, 38) . Another alternative explanation could be related to the presence of two or more sequential blocking sites in the pore (39, 40) . In agreement with this, studies of the action of the anthelmintic morantel at the muscle AChR from Ascaris have suggested a complex channel blockade mechanism that could be explained by the presence of two blocking sites within the channel pore (41) .
Electrophysiological studies on Ascaris muscle have shown that the dissociation constant of levamisole for channel block (K B ) is 123 M at Ϫ50 mV (1). This value is similar to the one calculated for mammalian AChRs in our study. Therefore, although the activation by levamisole is strikingly different between mammalian and nematode muscle AChRs, the open channel blockade seems to be similar. This confirms that blockade is not involved in the differential selectivity of anthelmintics on both types of muscles.
Levamisole and pyrantel are believed to share the same mechanism of action although they have quite different chemical structures. Pyrantel is a tetrahydropyrimidine, whereas levamisole is an imidazothiazole. By single channel recordings, we have shown previously (42) that pyrantel acts as a low efficacious agonist and a high affinity open channel blocker of the mammalian muscle AChRs. Our results indicate that levamisole is less potent than pyrantel to activate as well as to block the mammalian AChR (42) . The calculated affinity K B for levamisole is 20-fold higher than that of pyrantel (8 M at Ϫ70 mV). Due to the weak agonist activity of pyrantel at mammalian AChRs, it is therefore probable that its toxic effects are mediated by its blocking activity. Our results, which show that the channel-blocking ability of pyrantel is higher than levami-sole, are in agreement with the reports that pyrantel has more toxic effects than levamisole (1) .
Finally, resistance to the anthelmintics pyrantel and levamisole is an increasingly widespread problem in gastrointestinal nematode infestations. Assuming that our findings in the mammalian AChR can be directly extrapolated to the nematode AChR, and although this requires direct confirmation in the nematode AChR, it would be interesting to determine whether mutations at ␣Glu-153 are involved in the development of resistance of the parasite against anthelmintics.
